India, April 15 -- Biocon Biologics Ltd. (BBL), a global, fully integrated biosimilars company and a subsidiary of Biocon Ltd, has announced a settlement and license agreement with Regeneron, paving the way for the commercialization of YESAFILI™ (aflibercept-jbvf) in the United States.
YESAFILI™, an interchangeable* biosimilar to EYLEA® (aflibercept), is a vascular endothelial growth factor (VEGF) inhibitor used to treat a range of ophthalmic conditions. This agreement resolves the ongoing appeal at the United States Court of Appeals for the Federal Circuit concerning the US11084865 ('865 patent), as well as the related litigation in the U.S. District Court for the Northern District of West Virginia (Clarksburg Division).
...